Abstract 180P
Background
Along with the prolonged survival of cancer patients in recent years comes another dilemma, multiple primary cancers (MPC), which rob cancer patients of their privilege to optimal treatments. Nonetheless, understanding the hereditary and postnatal predisposition of MPC is still in its infancy.
Methods
We included 47,550 cancer patients in UK Biobank. Hazardous and protective HLA alleles concerning MPC were recognized leveraging stepwise logistic regression, which was further validated by log-rank test and Cox proportional hazard model. Logistic regression was used to investigate the organ-specific association between HLA and MPC. Cox proportional hazard model was used to explore potential interventions.
Results
Two protective (DPA1*02:02 and DRB1*04:03) and four hazardous (A*26:01, A*24:03, DPB1*20:01 and DQB1*06:01) HLA alleles are significantly associated with MPC risk for male, whereas one protective (DRB5*01:01) and four hazardous (A*03:02, DRB1*08:03, DQB1*05:04, and DPB1*11:01) for female. Compared with patients without MPC-related HLA alleles, both male and female patients carrying protective HLA alleles have lower risk of MPC (HR, 0.67 [95% CI, 0.53-0.83] and HR, 0.84 [95% CI, 0.73-0.97], respectively), while those carrying hazardous HLA alleles have higher risk of MPC (HR, 1.31 [95% CI, 1.09-1.57] and HR, 1.55 [95% CI, 1.25-1.93], respectively). HLA alleles are associated with organ-specific MPC occurrence. Lower animal fat intake subsided (HR, 0.46 [95% CI, 0.26-0.82]) while unqualified vegetable fat intake increased MPC risk (HR, 2.23 [95% CI, 1.22-4.07]) for male cancer patients carrying hazardous HLA alleles. Lower free sugar intake subsided the risk of MPC for female patients carrying hazardous HLA alleles (HR, 0.34 [95% CI, 0.15-0.74]).
Conclusions
HLA alleles might help to understand the predisposition and organ-specific incidence of MPC. Intervention on diet could counteract the risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongyi Dong.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
186P - Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials
Presenter: Marco Tagliamento
Session: Poster session 01
187P - Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial
Presenter: Christoph Heilig
Session: Poster session 01
188P - The landscape of SMARCA2 genomic alterations in Chinese cancer patients
Presenter: Chen Jiaqi
Session: Poster session 01
189P - Design and enrollment for a classifier development study for a blood-based multi-cancer early detection (MCED) test
Presenter: Christopher Douville
Session: Poster session 01
190P - Quantitative serum tumor markers (CEA, CA19-9, and CA-125) are independently predictive of survival in patients with appendiceal adenocarcinoma
Presenter: John Paul Shen
Session: Poster session 01
191P - Novel approach to proficiency testing demonstrates wide gaps in biomarker quality for colon cancer treatment
Presenter: Kassandra Bisson, Brandon Sheffield
Session: Poster session 01
192P - Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting
Presenter: Hussein Sweiti
Session: Poster session 01
194P - Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
Presenter: Dominik Barth
Session: Poster session 01
195P - Identification of biomarkers associated with checkpoint inhibitor pneumonitis based on serum proteomic approach and construction of an online interactive visual prediction model
Presenter: Xiaohui Jia
Session: Poster session 01
196P - Serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts
Presenter: Yanjun Xu
Session: Poster session 01